EXEL Exelixis Inc

Price (delayed)

$21.66

Market cap

$6.76B

P/E Ratio

60.17

Dividend/share

N/A

EPS

$0.36

Enterprise value

$6.49B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's equity rose by 11% YoY
The gross profit has grown by 3.4% from the previous quarter
The P/E is 62% above the last 4 quarters average of 37.1 but 19% below the 5-year quarterly average of 74.4
The company's EPS has shrunk by 66% YoY and by 28% QoQ
The company's net income has shrunk by 65% YoY and by 27% QoQ

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
311.99M
Market cap
$6.76B
Enterprise value
$6.49B
Valuations
Price to earnings (P/E)
60.17
Price to book (P/B)
3.58
Price to sales (P/S)
6.76
EV/EBIT
49.59
EV/EBITDA
44.8
EV/Sales
6.57
Earnings
Revenue
$987.54M
EBIT
$130.84M
EBITDA
$144.81M
Free cash flow
$178.64M
Per share
EPS
$0.36
Free cash flow per share
$0.58
Book value per share
$6.06
Revenue per share
$3.2
TBVPS
$6.73
Balance sheet
Total assets
$2.14B
Total liabilities
$258.22M
Debt
$49.09M
Equity
$1.88B
Working capital
$1.24B
Liquidity
Debt to equity
0.03
Current ratio
7.06
Quick ratio
6.68
Net debt/EBITDA
-1.87
Margins
EBITDA margin
14.7%
Gross margin
96.3%
Net margin
11.3%
Operating margin
11.1%
Efficiency
Return on assets
5.4%
Return on equity
6.1%
Return on invested capital
8.8%
Return on capital employed
6.8%
Return on sales
13.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
-1.37%
1 week
-2.48%
1 month
-3.56%
1 year
15.89%
YTD
7.92%
QTD
7.92%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$987.54M
Gross profit
$951.27M
Operating income
$110.06M
Net income
$111.78M
Gross margin
96.3%
Net margin
11.3%
EXEL's operating margin has dropped by 71% year-on-year and by 35% since the previous quarter
Exelixis's operating income has shrunk by 70% YoY and by 33% QoQ
The net margin has plunged by 66% YoY and by 29% from the previous quarter
The company's net income has shrunk by 65% YoY and by 27% QoQ

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
P/E
60.17
P/B
3.58
P/S
6.76
EV/EBIT
49.59
EV/EBITDA
44.8
EV/Sales
6.57
The company's EPS has shrunk by 66% YoY and by 28% QoQ
The P/E is 62% above the last 4 quarters average of 37.1 but 19% below the 5-year quarterly average of 74.4
EXEL's P/B is 82% below its 5-year quarterly average of 20.1
The company's equity rose by 11% YoY
EXEL's price to sales (P/S) is 49% lower than its 5-year quarterly average of 13.2
The revenue has grown by 3.1% from the previous quarter and by 2% YoY

Efficiency

How efficient is Exelixis business performance
The ROIC has plunged by 73% YoY and by 32% from the previous quarter
The ROA has plunged by 71% YoY and by 29% from the previous quarter
The company's return on equity has shrunk by 71% YoY and by 28% QoQ
The company's return on sales has shrunk by 68% YoY and by 33% QoQ

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
The debt is 97% less than the equity
The debt has increased by 3.1% from the previous quarter and by 2.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.